BioCorRx (BICX) Common Equity (2016 - 2025)
BioCorRx (BICX) has disclosed Common Equity for 16 consecutive years, with -$11.5 million as the latest value for Q4 2025.
- Quarterly Common Equity rose 6.7% to -$11.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$11.5 million through Dec 2025, up 6.7% year-over-year, with the annual reading at -$11.5 million for FY2025, 6.7% up from the prior year.
- Common Equity hit -$11.5 million in Q4 2025 for BioCorRx, down from $16000.0 in the prior quarter.
- In the past five years, Common Equity ranged from a high of $11.8 million in Q1 2025 to a low of -$12.4 million in Q4 2024.
- Historically, Common Equity has averaged -$6.7 million across 5 years, with a median of -$7.8 million in 2022.
- Biggest five-year swings in Common Equity: crashed 93.72% in 2022 and later skyrocketed 208.59% in 2025.
- Year by year, Common Equity stood at -$7.0 million in 2021, then decreased by 17.82% to -$8.2 million in 2022, then dropped by 21.35% to -$10.0 million in 2023, then fell by 24.14% to -$12.4 million in 2024, then increased by 6.7% to -$11.5 million in 2025.
- Business Quant data shows Common Equity for BICX at -$11.5 million in Q4 2025, $16000.0 in Q3 2025, and $17282.0 in Q2 2025.